{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:02:17Z","timestamp":1768312937617,"version":"3.49.0"},"reference-count":122,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0172206","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T18:54:46Z","timestamp":1487357686000},"page":"e0172206","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2341-5319","authenticated-orcid":true,"given":"Michael E.","family":"Abram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee R.","family":"Ram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas A.","family":"Margot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany L.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten L.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/QAI.0b013e31819675e9","article-title":"The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time","volume":"50","author":"VD Lima","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"ref2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMra1004180","article-title":"Development of antiretroviral drug resistance","volume":"365","author":"MA Wainberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/jac\/dkq139","article-title":"Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution","volume":"65","author":"JA Johnson","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"ref4","first-page":"51","article-title":"Viruses as quasispecies: biological implications","volume":"299","author":"E Domingo","year":"2006","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7074","key":"ref5","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature04388","article-title":"Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population","volume":"439","author":"M Vignuzzi","year":"2006","journal-title":"Nature"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrg1246","article-title":"The causes and consequences of HIV evolution","volume":"5","author":"A Rambaut","year":"2004","journal-title":"Nature reviews Genetics"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1086\/528802","article-title":"Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects","volume":"197","author":"DR Kuritzkes","year":"2008","journal-title":"J Infect Dis"},{"issue":"5","key":"ref8","first-page":"662","article-title":"Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure","volume":"201","author":"R Paredes","year":"2010","journal-title":"J Infect Dis"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/595703","article-title":"Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients","volume":"48","author":"KJ Metzner","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy","volume":"5","author":"JA Johnson","year":"2008","journal-title":"PLoS Med"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes","volume":"199","author":"BB Simen","year":"2009","journal-title":"J Infect Dis"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study","volume":"11","author":"L Wittkop","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ref13","first-page":"17","article-title":"Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world","volume":"14","author":"D Frentz","year":"2012","journal-title":"AIDS Rev"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/jac\/dkr157","article-title":"Evolutionary pathways of transmitted drug-resistant HIV-1","volume":"66","author":"M Pingen","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3851\/IMP1750","article-title":"Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule","volume":"16","author":"CB Hurt","year":"2011","journal-title":"Antivir Ther"},{"key":"ref16","unstructured":"Department for Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents\u2014A Working Group of the Office of AIDS Research Advisory Council (OARAC); <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf\" xlink:type=\"simple\">http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf<\/ext-link>. 2016."},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel","volume":"316","author":"HF Gunthard","year":"2016","journal-title":"JAMA"},{"key":"ref18","unstructured":"Merck Sharp &amp; Dohme Corp. ISENTRESS<sup>\u00ae<\/sup> (raltegravir) film-coated tablets, for oral use. ISENTRESS<sup>\u00ae<\/sup> (raltegravir) chewable tablets, for oral use. ISENTRESS<sup>\u00ae<\/sup> (raltegravir) for oral suspension. U.S. Prescribing Information. New Jersey, USA. 2015."},{"key":"ref19","unstructured":"Gilead Sciences Inc. VITEKTA<sup>\u00ae<\/sup> (elvitegravir) tablets, for oral use. U.S. Prescribing Information. Foster City, CA. 2014."},{"key":"ref20","unstructured":"GlaxoSmithKline. TIVICAY (dolutegravir) tablets for oral use. U.S. Prescribing Information. Research Triangle Park, NC. 2015."},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study","volume":"46","author":"M Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials","volume":"50","author":"RT Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e31828ace69","article-title":"Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir\/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK","volume":"63","author":"JK Rockstroh","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1086\/650698","article-title":"Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial","volume":"201","author":"AR Zolopa","year":"2010","journal-title":"J Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1473-3099(11)70249-3","article-title":"Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study","volume":"12","author":"JM Molina","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","article-title":"A randomized, double-blind comparison of tenofovir alafenamide (TAF) vs. tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for initial HIV-1 treatment: week 96 results","volume":"72","author":"D Wohl","year":"2016","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/QAI.0000000000000089","article-title":"A randomized, double-blind comparison of single-tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine\/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results","volume":"65","author":"N Clumeck","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"F Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"9893","key":"ref29","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"P Cahn","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"S Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/14787210.2015.1075393","article-title":"Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection","volume":"13","author":"TE Park","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009\u20132012","volume":"58","author":"CB Hurt","year":"2014","journal-title":"Clin Infect Dis"},{"key":"ref33","unstructured":"Gilead Sciences Inc. STRIBILD<sup>\u00ae<\/sup> (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) tablets, for oral use. U.S. Prescribing Information. Foster City, CA. 2016."},{"key":"ref34","unstructured":"Gilead Sciences Inc. GENVOYA<sup>\u00ae<\/sup> (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use. US Prescribing Information. Foster City, CA. 2016."},{"key":"ref35","unstructured":"ViiV Healthcare. TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets, for oral use. Research Triangle Park, NC. US Prescribing Information. 2014."},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3851\/IMP1749","article-title":"Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient","volume":"16","author":"SD Boyd","year":"2011","journal-title":"Antivir Ther"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/2325957415596229","article-title":"Five antiretroviral drug class-resistant HIV-1 in a treatment-naive patient successfully suppressed with optimized antiretroviral drug selection","volume":"14","author":"JM Volpe","year":"2015","journal-title":"Journal of the International Association of Providers of AIDS Care"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3851\/IMP1748","article-title":"Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy","volume":"16","author":"B Young","year":"2011","journal-title":"Antivir Ther"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.antiviral.2010.09.016","article-title":"Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure","volume":"88","author":"FM Codoner","year":"2010","journal-title":"Antiviral Res"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.coviro.2012.08.004","article-title":"The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance","volume":"2","author":"M Gotte","year":"2012","journal-title":"Current opinion in virology"},{"issue":"13","key":"ref41","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1128\/JVI.06618-11","article-title":"Substitutions at amino acid positions 143, 148, and 155 of HIV- 1 integrase define distinct genetic barriers to raltegravir resistance in vivo","volume":"86","author":"S Fransen","year":"2012","journal-title":"J Virol"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"e40514","DOI":"10.1371\/journal.pone.0040514","article-title":"Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations","volume":"7","author":"MA Winters","year":"2012","journal-title":"PLoS ONE"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro","volume":"52","author":"I Malet","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"22","key":"ref44","doi-asserted-by":"crossref","first-page":"11440","DOI":"10.1128\/JVI.01168-09","article-title":"Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways","volume":"83","author":"S Fransen","year":"2009","journal-title":"J Virol"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1128\/AAC.02568-12","article-title":"Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness","volume":"57","author":"ME Abram","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.antiviral.2008.10.007","article-title":"Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics","volume":"81","author":"K Nakahara","year":"2009","journal-title":"Antiviral Res"},{"issue":"9","key":"ref47","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/AAC.00204-13","article-title":"Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir","volume":"57","author":"W Huang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref48","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/nar\/gkn1050","article-title":"The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation","volume":"37","author":"O Delelis","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"ref49","unstructured":"Goodman DD, Hluhanich R, Waters JM, Margot NA, Fransen S, Gupta S, et al., editors. Integrase inhibitor resistance involves complex interactions among primary and secondary resistance mutations: A novel mutation L68V\/I associates with E92Q and increases resistance [Poster 13]. XVII International HIV Drug Resistance Workshop; 2008 June 10\u201314; Stiges, Spain."},{"issue":"9","key":"ref50","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1128\/AAC.01720-09","article-title":"Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors","volume":"54","author":"F Ceccherini-Silberstein","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ref51","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dkq326","article-title":"Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors","volume":"65","author":"F Ceccherini-Silberstein","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/135965350701200411","article-title":"Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance","volume":"12","author":"M Lataillade","year":"2007","journal-title":"Antivir Ther"},{"issue":"18","key":"ref53","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1128\/JVI.01535-07","article-title":"Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase","volume":"82","author":"RE Myers","year":"2008","journal-title":"J Virol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1742-4690-6-12","article-title":"HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure","volume":"6","author":"SJ van Hal","year":"2009","journal-title":"Retrovirology"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1743-422X-8-149","article-title":"HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients","volume":"8","author":"A Piralla","year":"2011","journal-title":"Virology journal"},{"issue":"2","key":"ref56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/jac\/dkp423","article-title":"Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection","volume":"65","author":"C Garrido","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/jac\/dks474","article-title":"HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes","volume":"68","author":"S Reigadas","year":"2013","journal-title":"J Antimicrob Chemother"},{"issue":"13","key":"ref58","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1128\/JVI.00495-16","article-title":"HIV-1 protease, reverse transcriptase, and integrase variation","volume":"90","author":"SY Rhee","year":"2016","journal-title":"J Virol"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/dkp153","article-title":"Evolution of raltegravir resistance during therapy","volume":"64","author":"N Sichtig","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"ref60","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/jmv.22047","article-title":"Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors","volume":"83","author":"BG Brenner","year":"2011","journal-title":"J Med Virol"},{"key":"ref61","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","author":"T Doyle","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"ref62","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/jac\/dkr152","article-title":"Prevalence of resistance mutations related to integrase inhibitor S\/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients","volume":"66","author":"I Malet","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"ref63","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/aid.2010.0123","article-title":"HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir","volume":"26","author":"V Varghese","year":"2010","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"ref64","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1128\/AAC.00397-09","article-title":"Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors","volume":"53","author":"A Low","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1097\/QAD.0b013e32830f9703","article-title":"Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility","volume":"22","author":"K Van Baelen","year":"2008","journal-title":"AIDS"},{"issue":"4","key":"ref66","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistance HIV-1 infection","volume":"359","author":"DA Cooper","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"ref67","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/jac\/dkp014","article-title":"Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients","volume":"63","author":"I Malet","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.meegid.2016.06.047","article-title":"Differences among HIV-1 subtypes in drug resistance against integrase inhibitors","volume":"46","author":"YS Han","year":"2016","journal-title":"Infect Genet Evol"},{"issue":"3","key":"ref69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/fmb.13.10","article-title":"HIV-1 drug resistance: where do polymorphisms fit in?","volume":"8","author":"K Theys","year":"2013","journal-title":"Future microbiology"},{"issue":"1","key":"ref70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350901400108","article-title":"Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes","volume":"14","author":"AI Maiga","year":"2009","journal-title":"Antivir Ther"},{"issue":"11","key":"ref71","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/QAD.0b013e328348065a","article-title":"Clinical efficacy of raltegravir against B and non- B subtype HIV-1 in phase III clinical studies","volume":"25","author":"JK Rockstroh","year":"2011","journal-title":"AIDS"},{"issue":"2","key":"ref72","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jac\/dkv333","article-title":"Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals","volume":"71","author":"T Llacer Delicado","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"ref73","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkp477","article-title":"Genotypic\/phenotypic patterns of HIV-1 integrase resistance to raltegravir","volume":"65","author":"F Canducci","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"ref74","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1469-0691.2010.03375.x","article-title":"Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption","volume":"17","author":"F Canducci","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"ref75","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QAD.0b013e328323da60","article-title":"Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies","volume":"23","author":"F Canducci","year":"2009","journal-title":"AIDS"},{"issue":"1","key":"ref76","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0b013e3181da1287","article-title":"Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses","volume":"55","author":"JL Lennox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9692","key":"ref77","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"JL Lennox","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"ref78","doi-asserted-by":"crossref","first-page":"e10311","DOI":"10.1371\/journal.pone.0010311","article-title":"The HIV-1 integrase mutations Y143C\/R are an alternative pathway for resistance to raltegravir and impact the enzyme functions","volume":"5","author":"S Reigadas","year":"2010","journal-title":"PLoS ONE"},{"key":"ref79","unstructured":"Waters JM, Margot N, Hluhanich R, Svarovskaia J, Harris J, Borroto-Esoda K, et al. Evoluti on of resistance to the HIV integrase inhibitor (INI) elvitegravir can involve genotypic switching among primary INI resistance patterns [Poster P116]. XVIII International HIV Drug Resistance Workshop; 2009 June 9\u201313; Fort Myers, Florida."},{"issue":"5","key":"ref80","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment- experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"JJ Eron","year":"2013","journal-title":"J Infect Dis"},{"issue":"2","key":"ref81","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dku387","article-title":"Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance","volume":"70","author":"I Hardy","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"ref82","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1128\/AAC.00071-11","article-title":"Structure-analysis of the HIV-1 integrase Y143C\/R raltegravir resistance mutation in association with the secondary mutation T97A","volume":"55","author":"S Reigadas","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref83","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1128\/AAC.04844-14","article-title":"Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro","volume":"59","author":"T Seki","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"ref84","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1128\/AAC.00566-11","article-title":"Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages","volume":"55","author":"MD Marsden","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2012.04.007","article-title":"In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen","volume":"95","author":"JS Cavalcanti","year":"2012","journal-title":"Antiviral Res"},{"issue":"6","key":"ref86","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/jac\/dkv029","article-title":"HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia","volume":"70","author":"D Armenia","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref87","unstructured":"Fransen S, Frantzell A, Gupta S, Petropoulos C, Huang W. Comparison of raltegravir susceptible and resistant viruses define the contribution of secondary mutations to reductions in raltegravir susceptibility [Poster 556]. Conference on Retroviruses and Opportunistic Infections (CROI); 2010 16\u201319 February; San Francisco, CA."},{"key":"ref88","unstructured":"Haddad M, Huang W, Miller M, White K, Paquet A, Evans M, et al. Genotypic algorithm for predicting elvitegravir susceptibility: clinical validation and correlation with phenotype [Poster H-1574]. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2012 09\u201312 September; San Francisco, CA."},{"issue":"5","key":"ref89","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1310\/hct1504-218","article-title":"Week 144 resistance analysis of elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus atazanavir+ritonavir+emtricitabine\/tenofovir DF in antiretroviral- naive patients","volume":"15","author":"R Kulkarni","year":"2014","journal-title":"HIV Clin Trials"},{"issue":"1","key":"ref90","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/QAI.0b013e31815acab8","article-title":"Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine\/lamivudine and efavirenz in treatment-naive patients: 144-week analysis","volume":"47","author":"JR Arribas","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"ref91","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"JE Gallant","year":"2004","journal-title":"JAMA"},{"issue":"5, Part 1","key":"ref92","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006","article-title":"Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection","volume":"139","author":"K Squires","year":"2003","journal-title":"Ann Intern Med"},{"key":"ref93","unstructured":"McColl DJ, Fransen S, Gupta S, Parkin N, Margot N, Ledford R, et al., editors. Resistance and cross-resistance to first generation integrase inhibitors: Insights from a phase 2 study of Elvitegravir (GS-9137) [Poster 9]. 16th International HIV Drug Resistance Workshop; 2007 June 12\u201316; Bridgetown, Barbados."},{"key":"ref94","unstructured":"Gaur A, Abadi J, Wiznia A, Borkowsky W, Tudor-Williams G, Cunningham CK, et al., editors. Pharmacokinetics and safety of once-daily elvitegravir in HIV-infected adolescents [Poster 874]. 17th Conference on Retroviruses and Opportunistic Infections (CROI); 2010 February 16\u201319; San Francisco, CA."},{"issue":"3","key":"ref95","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/QAI.0000000000000057","article-title":"A randomized, double-blind comparison of single- tablet regimen elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus single-tablet regimen efavirenz\/emtricitabine\/tenofovir DF for initial treatment of HIV-1 infection: Analysis of Week 144 Results","volume":"65","author":"DA Wohl","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"ref96","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3851\/IMP2885","article-title":"Week 144 resistance analysis of elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus efavirenz\/emtricitabine\/tenofovir DF in antiretroviral-naive patients","volume":"20","author":"KL White","year":"2015","journal-title":"Antivir Ther"},{"issue":"6","key":"ref97","doi-asserted-by":"crossref","first-page":"F7","DOI":"10.1097\/QAD.0b013e328345766f","article-title":"Randomized, phase 2 evaluation of two single- tablet regimens elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate versus efavirenz\/emtricitabine\/tenofovir disoproxil fumarate for the initial treatment of HIV infection","volume":"25","author":"C Cohen","year":"2011","journal-title":"AIDS"},{"issue":"3","key":"ref98","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000000476","article-title":"Elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment","volume":"68","author":"FA Post","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref99","unstructured":"Kityo C, Squires K, Johnson M, Branco T, Post F, Kozyrev O, et al. The efficacy and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate and ritonavir-boosted atazanavir plus emtricitabine\/tenofovir disoproxil fumarate in treatment-na\u00efve women with HIV-1 infection: week 48 analysis of the phase 3, randomized, double-blind study [Poster 296]. European AIDS Clinical Society (EACS); 2015 21\u201324 October; Barcelona, Spain."},{"issue":"1","key":"ref100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study","volume":"67","author":"PE Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/15284336.2016.1142731","article-title":"Rare emergence of drug resistance in HIV-1 treatment -naive patients after 48 weeks of treatment with elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","volume":"17","author":"NA Margot","year":"2016","journal-title":"HIV Clin Trials"},{"key":"ref102","unstructured":"Kizito H, Gaur A, Prasitsuebsai W, Rakhmanina N, Lawson E, Shao Y, et al. Safety, efficacy and pharmacokinetics of the integrase inhibitor-based E\/C\/F\/TAF single-tablet regimen in treatment-na\u00efve HIV-infected adolescents through 24 weeks of treatment [Poster 953]. Conference on Retroviruses and Opportunistic Infections; 2015 February 23\u201326; Seattle, WA."},{"key":"ref103","unstructured":"Abram M, Margot NA, Cox S, Ram R, Porter DP, Kitrinos KM, et al. Pooled week 48 analysis of HIV-1 drug resistance in E\/C\/F\/TAF phase 3 studies [Poster 496]. 23rd Annual Conference on Retroviruses and Opportunistic Infections (CROI); 2016 22\u201325 February; Boston, MA."},{"key":"ref104","unstructured":"Fransen S, Gupta A, Huang W, Petropoulos C, Kiss L, Parkin N. Performance characteristics and validation of the phenosense HIV integrase assay [Poster H-1214]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2008 25\u201328 October; Washington, DC."},{"issue":"11","key":"ref105","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"TF Liu","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref106","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.antiviral.2011.03.178","article-title":"Resistance associated mutations to dolutegravir (S\/GSK1349572) in HIV-infected patients\u2014impact of HIV subtypes and prior raltegravir experience","volume":"90","author":"C Garrido","year":"2011","journal-title":"Antiviral Res"},{"issue":"1","key":"ref107","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1310\/hct1401-10","article-title":"Prevalence of primary resistance mutations to integrase inhibitors in treatment-naive and -experienced patients infected with B and non-B HIV-1 variants","volume":"14","author":"C Gutierrez","year":"2013","journal-title":"HIV Clin Trials"},{"issue":"1","key":"ref108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2780","article-title":"Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007\u20132013","volume":"20","author":"JD Stekler","year":"2015","journal-title":"Antivir Ther"},{"issue":"3","key":"ref109","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1128\/AAC.01492-10","article-title":"Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment","volume":"55","author":"J Liu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref110","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/aid.2011.0326","article-title":"Group AAAW. Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations","volume":"28","author":"M Monleau","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"ref111","doi-asserted-by":"crossref","first-page":"e6687","DOI":"10.1371\/journal.pone.0006687","article-title":"HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins","volume":"4","author":"ZL Brumme","year":"2009","journal-title":"PLoS ONE"},{"issue":"9","key":"ref112","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"JL Blanco","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"ref113","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/AAC.01791-12","article-title":"Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S\/GSK1349572)","volume":"57","author":"C Vavro","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref114","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jir821","article-title":"Study of genotypic and phenotypic HIV- 1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing","volume":"205","author":"D Armenia","year":"2012","journal-title":"J Infect Dis"},{"issue":"4","key":"ref115","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/135965350400900420","article-title":"Clinically validated genotype analysis: guiding principles and statistical concerns","volume":"9","author":"F Brun-Vezinet","year":"2004","journal-title":"Antivir Ther"},{"issue":"2","key":"ref116","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350200700206","article-title":"A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients","volume":"7","author":"K Van Laethem","year":"2002","journal-title":"Antivir Ther"},{"issue":"2","key":"ref117","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000331998","article-title":"The HIVdb system for HIV-1 genotypic resistance interpretation","volume":"55","author":"MW Tang","year":"2012","journal-title":"Intervirology"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2015.04.014","article-title":"Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance","volume":"119","author":"A Hachiya","year":"2015","journal-title":"Antiviral Res"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.pharmtox.011008.145553","article-title":"Emerging pharmacology: inhibitors of human immunodeficiency virus integration","volume":"49","author":"D Hazuda","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"ref120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","author":"S Ramanathan","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"ref121","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijantimicag.2013.02.016","article-title":"A cohort study of treatment- experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure","volume":"42","author":"AG Marcelin","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"14","key":"ref122","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1097\/QAD.0b013e32833cf265","article-title":"HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays","volume":"24","author":"T Bar-Magen","year":"2010","journal-title":"AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0172206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T11:21:42Z","timestamp":1658661702000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0172206"}},"subtitle":[],"editor":[{"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":122,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0172206","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]}}}